Mylan NV (NASDAQ:MYL) – Svb Leerink dropped their Q2 2019 EPS estimates for Mylan in a report released on Tuesday, May 7th. Svb Leerink analyst A. Fadia now forecasts that the company will earn $0.98 per share for the quarter, down from their prior forecast of $1.00. Svb Leerink also issued estimates for Mylan’s FY2020 earnings at $4.92 EPS.
MYL has been the topic of a number of other research reports. Zacks Investment Research cut shares of Mylan from a “buy” rating to a “hold” rating in a research report on Monday, January 14th. UBS Group cut shares of Mylan from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $54.00 to $32.00 in a research report on Wednesday, January 23rd. Mizuho reissued a “neutral” rating on shares of Mylan in a research report on Thursday, January 31st. Sanford C. Bernstein cut shares of Mylan from an “outperform” rating to a “market perform” rating and set a $33.00 price objective on the stock. in a research report on Wednesday, February 27th. Finally, BMO Capital Markets increased their price objective on shares of Mylan to $40.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 27th. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have issued a buy rating to the stock. Mylan currently has an average rating of “Buy” and a consensus target price of $37.35.
Mylan (NASDAQ:MYL) last issued its quarterly earnings results on Tuesday, May 7th. The company reported $0.82 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.79 by $0.03. Mylan had a return on equity of 18.96% and a net margin of 2.14%. The firm had revenue of $2.50 billion during the quarter, compared to the consensus estimate of $2.70 billion. During the same period last year, the business posted $0.96 EPS. The business’s revenue was down 7.0% compared to the same quarter last year.
In other Mylan news, insider Paul Campbell sold 11,533 shares of the stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $27.50, for a total value of $317,157.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.81% of the company’s stock.
A number of large investors have recently bought and sold shares of MYL. Norges Bank purchased a new stake in Mylan in the 4th quarter valued at about $169,463,000. Oregon Public Employees Retirement Fund increased its stake in Mylan by 2,715.0% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 6,145,628 shares of the company’s stock valued at $224,000 after buying an additional 5,927,314 shares during the last quarter. State of New Jersey Common Pension Fund D increased its stake in Mylan by 194.0% in the 1st quarter. State of New Jersey Common Pension Fund D now owns 1,700,000 shares of the company’s stock valued at $48,178,000 after buying an additional 1,121,745 shares during the last quarter. State of Tennessee Treasury Department increased its stake in Mylan by 644.2% in the 4th quarter. State of Tennessee Treasury Department now owns 1,226,063 shares of the company’s stock valued at $33,595,000 after buying an additional 1,061,320 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in Mylan by 15.0% in the 4th quarter. Geode Capital Management LLC now owns 7,875,204 shares of the company’s stock valued at $215,460,000 after buying an additional 1,026,731 shares during the last quarter. Hedge funds and other institutional investors own 83.45% of the company’s stock.
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
See Also: Diversification Important in Investing
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.